The biotech company, with the support of the Galician Innovation Agency, will develop this project for a year and a half, contributing to the development of Lugo’s innovative ecosystem.

AMSbiopharma, a CRO (Contract Research Organization) laboratory based in Lugo specialised in advanced analytical services for the chemical, pharmaceutical and biopharmaceutical industry in pre-clinical and clinical phases, designs and launches its new Innovation Plan to position itself as a European benchmark in services to biopharmaceutical companies in the development of new drugs. AMSbiopharma, part of the AMSlab group, which has the support of the Galician Innovation Agency for this project, also specialises in drug quality control.

AMSbiopharma, with more than five years of experience, has already demonstrated a “constant commitment to innovation”. Its new plan seeks “not only to strengthen its operational capacity, but also to differentiate itself from its competitors by implementing new analysis and quality control services in drug manufacturing”. The incorporation of advanced services will be key to ensuring higher quality and safety products.

Innovation, AMSbiopharma’s DNA

AMSbiopharma’s Innovation Plan is not only limited to improving internal processes, but adopts a comprehensive approach that encompasses innovation in services, technology and organisation. At the heart of this project is innovative intrapreneurship and the valorisation of intangible innovation, a process of disruptive diversification that encourages employees to take on an entrepreneurial role in the company through existing know-how, synergies and new knowledge. AMSbiopharma will thus be able to develop creative solutions and implement innovative projects that respond to the demands of a constantly evolving market.

The Innovation Plan includes the implementation of new technologies such as encryption and data control to improve traceability and transparency in manufacturing processes. This development optimises process efficiency and reinforces the safety and reliability of AMSbiopharma’s services.

Support from the Axencia Galega de Innovación

The AMSbiopharma Innovation Plan, which will be developed over 18 months, is subsidised by the Axencia Galega de Innovación, through the InnovaPeme business aid programme, in its 2024 call for proposals. To ensure its success, AMSbiopharma has reinforced its team with the recruitment of new staff, chosen under strict selection criteria.

AMSbiopharma, through this innovative initiative, strengthens its competitive position in the market and contributes to the development of biotechnology in Lugo. The commitment to technological innovation and continuous process improvement will allow the company to offer services of the highest quality, reaffirming its commitment to excellence in the biopharmaceutical industry.

More information: Bioga Press. 679.486.961.
For BIOGA, it is a priority to promote intersectoral collaboration with other entities and to promote national and international networking activities. If you want to know more about us, please visit the following link.